ROBERT DAVID SCHREIBER

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling
    Chilakamarti V Ramana
    Lerner Research Institute, The Cleveland Clinic Foundation, OH 44195, USA
    Trends Immunol 23:96-101. 2002
  2. ncbi Cytokine signaling in 2002: new surprises in the Jak/Stat pathway
    JOHN J O'SHEA
    Molecular Immunology and Inflammation Branch, National Institutes of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    Cell 109:S121-31. 2002
  3. pmc STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system
    Jianping Wang
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:16209-14. 2002
  4. ncbi Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection
    Kathleen C F Sheehan
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Interferon Cytokine Res 26:804-19. 2006
  5. doi Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
    Robert D Schreiber
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 331:1565-70. 2011
  6. pmc Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
    Hirokazu Matsushita
    Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Nature 482:400-4. 2012
  7. pmc Type I interferon is selectively required by dendritic cells for immune rejection of tumors
    Mark S Diamond
    Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA
    J Exp Med 208:1989-2003. 2011
  8. pmc STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas
    Szeman Ruby Chan
    Department of Pathology and Immunology, Washington University School of Medicine, 425 S, Euclid Avenue, St, Louis, MO 63110, USA
    Breast Cancer Res 14:R16. 2012
  9. ncbi Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain
    R M Weber-Nordt
    Center for Immunology, Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 271:27954-61. 1996
  10. ncbi The roles of IFN gamma in protection against tumor development and cancer immunoediting
    Hiroaki Ikeda
    Department of Pathology and Immunology, Center for Immunology, School of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cytokine Growth Factor Rev 13:95-109. 2002

Research Grants

  1. THE ROLE OF THE INTERFERONS IN CANCER IMMUNOEDITING
    ROBERT DAVID SCHREIBER; Fiscal Year: 2010
  2. IL-10 Receptor Signaling That Regulates Innate Immunity
    Robert Schreiber; Fiscal Year: 2005
  3. IFNgamma Receptor Signaling Dysfuction in Cancer
    Robert Schreiber; Fiscal Year: 2005
  4. IL-10 Receptor Signaling That Regulates Innate Immunity
    Robert Schreiber; Fiscal Year: 2006
  5. The Molecular and Cellular Basis of Cancer Immunoediting
    Robert Schreiber; Fiscal Year: 2006
  6. IFNgamma Receptor Signaling Dysfuction in Cancer
    Robert Schreiber; Fiscal Year: 2007
  7. TRAINING IN CANCER BIOLOGY
    Robert Schreiber; Fiscal Year: 2007
  8. Jaks and Stats: Development to Disease
    Robert Schreiber; Fiscal Year: 2004
  9. IL-10 Receptor Signaling That Regulates Innate Immunity
    Robert Schreiber; Fiscal Year: 2004
  10. MOLECULAR REGULATION OF MACROPHAGE CYTOCIDAL ACTIVITY
    Robert Schreiber; Fiscal Year: 1990

Collaborators

Detail Information

Publications43

  1. ncbi Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling
    Chilakamarti V Ramana
    Lerner Research Institute, The Cleveland Clinic Foundation, OH 44195, USA
    Trends Immunol 23:96-101. 2002
    ..The diversity of gene-expression patterns mediated by Stat1-dependent and -independent mechanisms and the balance between these two pathways play an important role in the biological response to IFN-gamma...
  2. ncbi Cytokine signaling in 2002: new surprises in the Jak/Stat pathway
    JOHN J O'SHEA
    Molecular Immunology and Inflammation Branch, National Institutes of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    Cell 109:S121-31. 2002
    ..This review focuses on recent advances in the field and highlights some of the most active areas of Jak-Stat pathway research...
  3. pmc STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system
    Jianping Wang
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:16209-14. 2002
    ..Finally, STAT1 or a downstream component of the JAKSTAT pathway may protect against such IFN-alpha-mediated injury in the CNS...
  4. ncbi Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection
    Kathleen C F Sheehan
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Interferon Cytokine Res 26:804-19. 2006
    ..These mAbs represent much needed tools to more clearly elucidate the biochemistry, cell biology, and physiologic function of the type I IFNs and their receptor in mediating host-protective immunity and immunopathology...
  5. doi Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
    Robert D Schreiber
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 331:1565-70. 2011
    ..Here, we discuss a unifying conceptual framework called "cancer immunoediting," which integrates the immune system's dual host-protective and tumor-promoting roles...
  6. pmc Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
    Hirokazu Matsushita
    Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Nature 482:400-4. 2012
    ....
  7. pmc Type I interferon is selectively required by dendritic cells for immune rejection of tumors
    Mark S Diamond
    Department of Pathology and Immunology, School of Medicine, Washington University in St Louis, St Louis, MO, USA
    J Exp Med 208:1989-2003. 2011
    ..Thus, DCs and specifically CD8α(+) DCs are functionally relevant targets of endogenous type I IFN during lymphocyte-mediated tumor rejection...
  8. pmc STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas
    Szeman Ruby Chan
    Department of Pathology and Immunology, Washington University School of Medicine, 425 S, Euclid Avenue, St, Louis, MO 63110, USA
    Breast Cancer Res 14:R16. 2012
    ..Herein, we show that a subset of human breast cancers display reduced STAT1 expression and that mice lacking STAT1 surprisingly develop ERα+/PR+ mammary tumors...
  9. ncbi Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain
    R M Weber-Nordt
    Center for Immunology, Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 271:27954-61. 1996
    ....
  10. ncbi The roles of IFN gamma in protection against tumor development and cancer immunoediting
    Hiroaki Ikeda
    Department of Pathology and Immunology, Center for Immunology, School of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cytokine Growth Factor Rev 13:95-109. 2002
    ....
  11. ncbi Interferon-gamma and cancer immunoediting
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Immunol Res 32:231-45. 2005
    ..Our current work focuses on defining the molecular mechanisms that underlie cancer immunoediting and exploring the implications of this process for cancer immunotherapy...
  12. pmc The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis
    Deborah Veis Novack
    Washington University School of Medicine, 660 S Euclid Ave, Box 8301, St Louis, MO 63110, USA
    J Exp Med 198:771-81. 2003
    ..These data demonstrate a novel, biologically relevant means of regulating NF-kappaB signaling, with upstream control and kinetics distinct from the classical IkappaBalpha pathway...
  13. ncbi Cancer immunoediting: from immunosurveillance to tumor escape
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Nat Immunol 3:991-8. 2002
    ..In this review, we will summarize the historical and experimental basis of cancer immunoediting and discuss its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction...
  14. pmc DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes
    Andrea L Bredemeyer
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nature 456:819-23. 2008
    ....
  15. pmc The lymphotoxin LTalpha(1)beta(2) controls postnatal and adult spleen marginal sinus vascular structure and function
    Carlene L Zindl
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Immunity 30:408-20. 2009
    ....
  16. ncbi The immunobiology of cancer immunosurveillance and immunoediting
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8118, St Louis, Missouri 63110, USA
    Immunity 21:137-48. 2004
    ..The full understanding of the immunobiology of cancer immunosurveillance and immunoediting will hopefully stimulate development of more effective immunotherapeutic approaches to control and/or eliminate human cancers...
  17. ncbi Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?
    Jack D Bui
    Department of Pathology, University of California at San Diego, 9500 Gilman Drive MC 0612, La Jolla, CA 92093 0612, USA
    Curr Opin Immunol 19:203-8. 2007
    ..These apparent disparate effects of immunity on tumorigenesis provide a unique model for study of the decision-making process that dictates immune function within a tumor...
  18. ncbi Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation
    Amanda L Blasius
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Immunol 177:3260-5. 2006
    ..Finally, we show that BST2 resides within an intracellular compartment corresponding to the Golgi apparatus, and may be involved in trafficking secreted cytokines in IPC...
  19. ncbi A critical function for type I interferons in cancer immunoediting
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nat Immunol 6:722-9. 2005
    ..Therefore, type I interferons are important components of the cancer immunoediting process and function in a way that does not completely overlap the functions of IFN-gamma...
  20. ncbi Interferons, immunity and cancer immunoediting
    Gavin P Dunn
    Washington University School of Medicine, Department of Pathology and Immunology, Box 8118, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Nat Rev Immunol 6:836-48. 2006
    ..More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting...
  21. pmc ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions
    Brian K Weaver
    Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Mol Cell Biol 27:4603-16. 2007
    ..ABIN-3 is, thus, an IL-10-induced gene product capable of attenuating NF-kappaB in human macrophages yet is inoperative in mice and represents a basis for species-specific differences in IL-10 actions...
  22. ncbi Adaptive immunity maintains occult cancer in an equilibrium state
    Catherine M Koebel
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nature 450:903-7. 2007
    ..These results reveal that, in addition to destroying tumour cells and sculpting tumour immunogenicity, the immune system of a naive mouse can also restrain cancer growth for extended time periods...
  23. pmc A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice
    Jennifer C Miller
    Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA
    J Immunol 181:8492-503. 2008
    ..burgdorferi uses a previously unidentified receptor and a pathway traditionally associated with viruses and intracellular bacteria to initiate transcription of type I IFN and IFN-responsive genes and to initiate arthritis development...
  24. ncbi IFN-dependent down-regulation of the NKG2D ligand H60 on tumors
    Jack D Bui
    Center for Immunology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63310, USA
    J Immunol 176:905-13. 2006
    ..This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses...
  25. ncbi The three Es of cancer immunoediting
    Gavin P Dunn
    Department of Pathology and Immunology, Center for Immunology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Annu Rev Immunol 22:329-60. 2004
    ..quot; In this review, we summarize the history of the cancer immunosurveillance controversy and discuss its resolution and evolution into the three Es of cancer immunoediting--elimination, equilibrium, and escape...
  26. ncbi Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting
    Robert D Schreiber
    Center for Immunology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Cancer Immun 5:1. 2005
  27. ncbi IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response
    Hiroyoshi Nishikawa
    Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
    J Immunol 175:4433-40. 2005
    ..These findings support the idea that IFN-gamma regulates the generation/activation of CD4+ CD25+ regulatory T cells...
  28. pmc Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice
    Masaya Kobayashi
    Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
    J Clin Invest 111:1297-308. 2003
    ..Thus, this study clearly established a sequential innate and acquired immune mechanism for the development of Th1-dependent enterocolitis...
  29. doi Immune-mediated dormancy: an equilibrium with cancer
    Michele W L Teng
    Peter MacCallum Cancer Centre, Victoria, Australia
    J Leukoc Biol 84:988-93. 2008
    ..These findings form a framework for future studies aimed at validating immune-mediated cancer dormancy in humans with the hopes of devising new, immunotherapeutic strategies to treat established cancer...
  30. pmc Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody
    Ravindra Uppaluri
    Department of Otolaryngology, Washington University School of Medicine and John Cochran VA Medical Center, St Louis, MO, USA
    Transplantation 86:137-47. 2008
    ..However, analysis of CXCR3 expression and function has been hampered by a general lack of availability of a neutralizing anti-CXCR3 monoclonal antibody (mAb) for use in experimental models...
  31. pmc NF-kappa B-inducing kinase regulates selected gene expression in the Nod2 signaling pathway
    Qilin Pan
    Department of Immunology, IMM 12, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    Infect Immun 74:2121-7. 2006
    ..Specifically, we have linked NIK to the induction of the B-cell chemoattractant known as BLC and suggest that this chemokine may play a role in processes initiated by Nod2 activation that lead to improved host defense...
  32. ncbi Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency
    Stephanie Dupuis
    Laboratoire de Genetique Humaine des Maladies Infectieuses, Université de Paris René Descartes INSERM UMR550, Faculte de Medecine Necker Enfants Malades, 75015 Paris, France
    Nat Genet 33:388-91. 2003
    ..Viral multiplication was not inhibited by recombinant IFN-alpha/beta in cell lines from the two individuals. Inherited impairment of the STAT1-dependent response to human IFN-alpha/beta thus results in susceptibility to viral disease...
  33. pmc Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
    Jeremy B Swann
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 105:652-6. 2008
    ..Overall, these data not only confirm the key role that MyD88 plays in promoting tumor development but also demonstrate that inflammation-induced carcinogenesis and cancer immunoediting can indeed occur in the same mouse tumor model...
  34. ncbi IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation
    Anne Krug
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Immunol 169:6079-83. 2002
    ..Upon pathogen encounter, IPC positioning within the lymph node may be further directed by CCR7 and IPC secretion of inflammatory chemokines may attract other IPC, promoting cluster formation in lymph nodes...
  35. ncbi Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins
    Jack D Bui
    Center for Immunology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cancer Res 66:7301-9. 2006
    ....
  36. ncbi Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity
    Jennifer E Fenner
    Centre for Functional Genomics and Human Disease, Monash Institute of Medical Research, Monash University, Clayton 3168, Australia
    Nat Immunol 7:33-9. 2006
    ..Thus, SOCS1 is an important in vivo inhibitor of type I interferon signaling and contributes to balancing its beneficial antiviral versus detrimental proinflammatory effects on innate immunity...
  37. pmc Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease
    Ariane Chapgier
    Laboratory of Human Genetics of Infectious Diseases, University of Paris Rene Descartes, INSERM U550, Necker Medical School, Paris, France
    PLoS Genet 2:e131. 2006
    ..These STAT1 alleles define two forms of dominant STAT1 deficiency, depending on whether the mutations impair STAT1 phosphorylation or DNA binding...
  38. ncbi Perforin and granzymes have distinct roles in defensive immunity and immunopathology
    Serani L H van Dommelen
    Immunology and Virology Program, Centre for Ophthalmology and Visual Science, The University of Western Australia, Western Australia, Australia
    Immunity 25:835-48. 2006
    ....
  39. ncbi A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes
    Daniel J Gough
    Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, and University of Melbourne, Parkville 3054, Victoria, Australia
    J Biol Chem 282:938-46. 2007
    ..This represents a novel signal transduction pathway induced by IFNgamma that proceeds in parallel with conventional JAK/STAT signaling to activate ISGs...
  40. ncbi Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations
    Guillaume Vogt
    Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes INSERM U550, Necker Medical School, 156 rue de Vaugirard, 75015 Paris, France
    Nat Genet 37:692-700. 2005
    ..Thus, an unexpectedly high proportion of mutations that cause human genetic disease might lead to the creation of new N-glycosylation sites. Their pathogenic effects may be a direct consequence of the addition of N-linked carbohydrate...
  41. pmc Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells
    Hiroyoshi Nishikawa
    Second Department of Internal Medicine, Mie University School of Medicine, Mie 514 8507, Japan
    J Exp Med 201:681-6. 2005
    ..We propose that SEREX-defined self-antigens such as those used in this study represent self-antigens that elicit naturally occurring CD4(+) CD25(+) T reg cells...
  42. ncbi Type I IFN contributes to NK cell homeostasis, activation, and antitumor function
    Jeremy B Swann
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, 8006 Victoria, Australia
    J Immunol 178:7540-9. 2007
    ..This study demonstrates that endogenous type I IFN is a central mediator of NK cell antitumor responses...
  43. ncbi Breaking down the barriers to cancer immunotherapy
    Ellen Pure
    Wistar Institute and The Ludwig Institute for Cancer, Philadelphia, Pennsylvania 19104, USA
    Nat Immunol 6:1207-10. 2005
    ..Emerging insights into the mechanisms of activation and negative regulation of innate and adaptive immune cells are providing new opportunities for the development of safe and effective cancer vaccines...

Research Grants29

  1. THE ROLE OF THE INTERFERONS IN CANCER IMMUNOEDITING
    ROBERT DAVID SCHREIBER; Fiscal Year: 2010
    ..Identifying these cells and defining how they function may lead to new therapeutic strategies that use the immune system to fight cancer. ..
  2. IL-10 Receptor Signaling That Regulates Innate Immunity
    Robert Schreiber; Fiscal Year: 2005
    ..This work should identify the molecular basis for IL-10's anti-inflammatory effects and should thus provide us with novel strategies to nonspecifically enhance resistance to infectious agents by interfering with this signaling pathway. ..
  3. IFNgamma Receptor Signaling Dysfuction in Cancer
    Robert Schreiber; Fiscal Year: 2005
    ....
  4. IL-10 Receptor Signaling That Regulates Innate Immunity
    Robert Schreiber; Fiscal Year: 2006
    ..This work should identify the molecular basis for IL-10's anti-inflammatory effects and should thus provide us with novel strategies to nonspecifically enhance resistance to infectious agents by interfering with this signaling pathway. ..
  5. The Molecular and Cellular Basis of Cancer Immunoediting
    Robert Schreiber; Fiscal Year: 2006
    ..This work will provide the first molecular and mechanistic insights into the cancer immunoediting process and may also establish molecular guidelines to judge the extent to which a tumor has been edited. ..
  6. IFNgamma Receptor Signaling Dysfuction in Cancer
    Robert Schreiber; Fiscal Year: 2007
    ....
  7. TRAINING IN CANCER BIOLOGY
    Robert Schreiber; Fiscal Year: 2007
    ....
  8. Jaks and Stats: Development to Disease
    Robert Schreiber; Fiscal Year: 2004
    ..abstract_text> ..
  9. IL-10 Receptor Signaling That Regulates Innate Immunity
    Robert Schreiber; Fiscal Year: 2004
    ..This work should identify the molecular basis for IL-10's anti-inflammatory effects and should thus provide us with novel strategies to nonspecifically enhance resistance to infectious agents by interfering with this signaling pathway. ..
  10. MOLECULAR REGULATION OF MACROPHAGE CYTOCIDAL ACTIVITY
    Robert Schreiber; Fiscal Year: 1990
    ..These studies should help to better define the molecular basis of macrophage activation and provide new insights into the roles of IFN gamma and activated macrophages in promoting physiologically important immune responses...
  11. MOLECULAR REGULATION OF MACROPHAGE CYTOCIDAL ACTIVITY
    Robert Schreiber; Fiscal Year: 1992
    ..These studies should help to better define the molecular basis of macrophage activation and provide new insights into the roles of IFN gamma and activated macrophages in promoting physiologically important immune responses...
  12. MOLECULAR REGULATION OF MACROPHAGE CYTOCIDAL ACTIVITY
    Robert Schreiber; Fiscal Year: 1991
    ..These studies should help to better define the molecular basis of macrophage activation and provide new insights into the roles of IFN gamma and activated macrophages in promoting physiologically important immune responses...
  13. IFNgamma Receptor Signaling Dysfuction in Cancer
    Robert Schreiber; Fiscal Year: 2004
    ....
  14. The Molecular and Cellular Basis of Cancer Immunoediting
    Robert Schreiber; Fiscal Year: 2007
    ..This work will provide the first molecular and mechanistic insights into the cancer immunoediting process and may also establish molecular guidelines to judge the extent to which a tumor has been edited. ..
  15. IL-10 Receptor Signaling That Regulates Innate Immunity
    Robert Schreiber; Fiscal Year: 2007
    ..This work should identify the molecular basis for IL-10's anti-inflammatory effects and should thus provide us with novel strategies to nonspecifically enhance resistance to infectious agents by interfering with this signaling pathway. ..
  16. IFNgamma Receptor Signaling Dysfuction in Cancer
    Robert Schreiber; Fiscal Year: 2006
    ....
  17. The Molecular and Cellular Basis of Cancer Immunoediting
    Robert Schreiber; Fiscal Year: 2005
    ..This work will provide the first molecular and mechanistic insights into the cancer immunoediting process and may also establish molecular guidelines to judge the extent to which a tumor has been edited. ..
  18. MOLECULAR REGULATION OF MACROPHAGE CYTOCIDAL ACTIVITY
    Robert Schreiber; Fiscal Year: 1993
    ..These studies should help to better define the molecular basis of macrophage activation and provide new insights into the roles of IFN gamma and activated macrophages in promoting physiologically important immune responses...
  19. IFNgamma Receptor Signaling Dysfuction in Cancer
    Robert Schreiber; Fiscal Year: 2003
    ....
  20. The Molecular and Cellular Basis of Cancer Immunoediting
    Robert Schreiber; Fiscal Year: 2004
    ..This work will provide the first molecular and mechanistic insights into the cancer immunoediting process and may also establish molecular guidelines to judge the extent to which a tumor has been edited. ..